Huma’s $130m raise will scale its digital health platform

With the goal of bringing proactive, predictive care to all, Huma has $130 million financing from leading health and technology companies.
The investment arms of Bayer, Hitachi, Samsung, Sony Innovation Fund by IGV, Unilever and the PE fund HAT are financing Huma Therapeutics Ltd to the tune of approximately $130 million.

Longevity.Technology: This sizeable investment will scale Huma’s modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research and expand their presence globally after last year’s acquisition of AI and wearables companies Biobeat and Tarilian Laser Technologies.

As interventions lead to longer lifespans and an aging population, aging in place continues to gather investment and inform strategy at a government level; Longevity.Technology is preparing a market intelligence report on the sector, and this is available to pre-order.

Leaps by Bayer and Hitachi Ventures led the Huma Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.

Huma’s $130m raise will scale its digital health platform